135 related articles for article (PubMed ID: 24987915)
41. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
Mahdi H; Maurer KA; Nutter B; Rose PG
Int J Gynecol Cancer; 2015 Jun; 25(5):823-9. PubMed ID: 25828750
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?
Lennox GK; Eiriksson LR; Reade CJ; Leung F; Mojtahedi G; Atenafu EG; Ferguson SE; Murphy J; Diamandis EP; Kulasingam V; Bernardini MQ
Int J Gynecol Cancer; 2015 Jun; 25(5):809-14. PubMed ID: 25855958
[TBL] [Abstract][Full Text] [Related]
43. Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?
Yoshida A; Derchain SF; Pitta DR; Andrade LA; Sarian LO
Gynecol Oncol; 2016 Mar; 140(3):481-5. PubMed ID: 26825617
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
[TBL] [Abstract][Full Text] [Related]
45. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
Gao B; Lindemann K; Anderson L; Fereday S; Hung J; Alsop K; Tothill RW; Gebski V; Kennedy C; Balleine RL; ; Harnett PR; Bowtell DD; DeFazio A
Gynecol Oncol; 2016 Sep; 142(3):458-64. PubMed ID: 27444035
[TBL] [Abstract][Full Text] [Related]
46. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
47. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
48. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of HE4 in patients with ovarian cancer.
Yuan C; Li R; Yan S; Kong B
Clin Chem Lab Med; 2018 Jun; 56(7):1026-1034. PubMed ID: 29420303
[TBL] [Abstract][Full Text] [Related]
50. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
Yoshihara K; Tajima A; Yahata T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Kotera K; Masuzaki H; Tashiro H; Katabuchi H; Inoue I; Tanaka K
PLoS One; 2010 Mar; 5(3):e9615. PubMed ID: 20300634
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic and prognostic significance of serum CD26 level in Asian women with high-grade serous ovarian carcinoma.
Shao S; Wang C; Tian J; Zhang H; Wang S; Du Y
Future Oncol; 2019 Jun; 15(16):1863-1871. PubMed ID: 31140312
[No Abstract] [Full Text] [Related]
52. A nomogram model based on clinical markers for predicting malignancy of ovarian tumors.
Gao B; Zhao X; Gu P; Sun D; Liu X; Li W; Zhang A; Peng E; Xu D
Front Endocrinol (Lausanne); 2022; 13():963559. PubMed ID: 36506042
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients.
Battista MJ; Cotarelo C; Jakobi S; Steetskamp J; Makris G; Sicking I; Weyer V; Schmidt M
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1097-102. PubMed ID: 24728493
[TBL] [Abstract][Full Text] [Related]
54. Analysis of falsely elevated risk of ovarian malignancy algorithm in women with ovarian endometrioma.
Shin JJ; Lee YJ; Kim R; Lee da Y; Won KH; Jee BC
Obstet Gynecol Sci; 2016 Jul; 59(4):295-302. PubMed ID: 27462596
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis.
Jia MM; Deng J; Cheng XL; Yan Z; Li QC; Xing YY; Fan DM; Tian XY
Oncotarget; 2017 Feb; 8(6):9660-9671. PubMed ID: 28039447
[TBL] [Abstract][Full Text] [Related]
56. Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site.
Celik B; Bulut T; Yalcin AD
Pathol Oncol Res; 2020 Apr; 26(2):1145-1151. PubMed ID: 31165997
[TBL] [Abstract][Full Text] [Related]
57. The role of HE4 in ovarian cancer follow-up: a review.
Piovano E; Attamante L; Macchi C; Cavallero C; Romagnolo C; Maggino T; Landoni F; Gadducci A; Sartori E; Gion M; Zola P
Int J Gynecol Cancer; 2014 Oct; 24(8):1359-65. PubMed ID: 25054447
[TBL] [Abstract][Full Text] [Related]
58. A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
Mysona D; Pyrzak A; Purohit S; Zhi W; Sharma A; Tran L; Tran P; Bai S; Rungruang B; Ghamande S; She JX
Gynecol Oncol; 2019 Mar; 152(3):574-580. PubMed ID: 30578005
[TBL] [Abstract][Full Text] [Related]
59. Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer.
Steffensen KD; Waldstrøm M; Brandslund I; Lund B; Sørensen SM; Petzold M; Jakobsen A
Oncol Lett; 2016 Jun; 11(6):3967-3974. PubMed ID: 27313725
[TBL] [Abstract][Full Text] [Related]
60. Serum soluble Fas levels in ovarian cancer.
Hefler L; Mayerhofer K; Nardi A; Reinthaller A; Kainz C; Tempfer C
Obstet Gynecol; 2000 Jul; 96(1):65-9. PubMed ID: 10862844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
